Key facts
- This page summarizes Kevin MacDermott's Form 4 filing for cbdMD, Inc. (YCBD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 May 2022, 16:06.
Kevin MacDermott - 16 May 2022 Form 4 Insider Report for cbdMD, Inc. (YCBD)
- Reporting relationship
- President
- Issuer ticker
- YCBD
- Reported as of
- 16 May 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Kevin MacDermott
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Kevin MacDermott filed Form 4 for cbdMD, Inc. (YCBD) on 18 May 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
YCBD
transaction
Common Stock
Award
- Transaction value
- Shares
- +125,000
- Change %
- +12500%
- Price
- Shares after
- 126,000
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
YCBD
transaction
Derivative
Common Stock (Right to Buy)
Award
- Transaction value
- Shares
- +405,000
- Change %
- Price
- Shares after
- 405,000
- Date
- 16 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 405,000
- Exercise price
- $0.8400
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022.
Footnote F2
The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025.